CN1886402A - 嘧啶－2－胺衍生物及其作为a2b腺苷受体拮抗剂的用途 - Google Patents

嘧啶－2－胺衍生物及其作为a2b腺苷受体拮抗剂的用途 Download PDF

Info

Publication number
CN1886402A
CN1886402A CNA2004800346926A CN200480034692A CN1886402A CN 1886402 A CN1886402 A CN 1886402A CN A2004800346926 A CNA2004800346926 A CN A2004800346926A CN 200480034692 A CN200480034692 A CN 200480034692A CN 1886402 A CN1886402 A CN 1886402A
Authority
CN
China
Prior art keywords
branched
optional
compound
amine
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800346926A
Other languages
English (en)
Chinese (zh)
Inventor
B·比达尔胡安
C·埃斯特韦特里亚斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Publication of CN1886402A publication Critical patent/CN1886402A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2004800346926A 2003-10-02 2004-09-22 嘧啶－2－胺衍生物及其作为a2b腺苷受体拮抗剂的用途 Pending CN1886402A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200302275 2003-10-02
ES200302275A ES2229928B1 (es) 2003-10-02 2003-10-02 Nuevos derivados de pirimidin-2-amina.

Publications (1)

Publication Number Publication Date
CN1886402A true CN1886402A (zh) 2006-12-27

Family

ID=34507890

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800346926A Pending CN1886402A (zh) 2003-10-02 2004-09-22 嘧啶－2－胺衍生物及其作为a2b腺苷受体拮抗剂的用途

Country Status (24)

Country Link
US (1) US20070265273A1 (enExample)
EP (1) EP1668000A1 (enExample)
JP (1) JP2007507443A (enExample)
KR (1) KR20060097010A (enExample)
CN (1) CN1886402A (enExample)
AR (1) AR046170A1 (enExample)
AU (1) AU2004283800B8 (enExample)
BR (1) BRPI0415324A (enExample)
CA (1) CA2540765A1 (enExample)
CO (1) CO5690593A2 (enExample)
EC (1) ECSP066426A (enExample)
ES (1) ES2229928B1 (enExample)
IL (1) IL174771A0 (enExample)
MX (1) MXPA06003525A (enExample)
NO (1) NO20061952L (enExample)
NZ (1) NZ546266A (enExample)
PE (1) PE20050473A1 (enExample)
RU (1) RU2006114746A (enExample)
SG (1) SG149077A1 (enExample)
TW (1) TW200526645A (enExample)
UA (1) UA82563C2 (enExample)
UY (1) UY28529A1 (enExample)
WO (1) WO2005040155A1 (enExample)
ZA (1) ZA200602139B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115477653A (zh) * 2022-10-11 2022-12-16 安徽省庆云医药股份有限公司 一种曲拉西利关键中间体及曲拉西利的制备方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2391103C2 (ru) 2004-10-15 2010-06-10 Си Ви Терапьютикс, Инк. Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b
ES2270715B1 (es) * 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
DE102006046410A1 (de) * 2006-09-20 2008-03-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Prophylaxe oder Behandlung oder Diagnostik von ischämischen Krankheiten
ES2303776B1 (es) * 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
RU2471793C2 (ru) * 2007-06-08 2013-01-10 Байер Кропсайенс Аг Фунгицид на основе гетероциклил-пиримидинил-аминопроизводных
BRPI0813629A2 (pt) * 2007-07-26 2018-07-10 Novartis Ag derivados de pirimidina úteis no tratamento de condições inflamatórias ou alérgicas
WO2009026276A1 (en) 2007-08-22 2009-02-26 Irm Llc 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
WO2009026204A1 (en) * 2007-08-22 2009-02-26 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
AR079545A1 (es) 2009-12-21 2012-02-01 Bayer Cropscience Ag Tienilpiri(mi)dinilazol
SG183146A1 (en) * 2010-02-05 2012-09-27 Heptares Therapeutics Ltd 1,2,4-triazine-4-amine derivatives
WO2012085815A1 (en) 2010-12-21 2012-06-28 Novartis Ag Bi-heteroaryl compounds as vps34 inhibitors
JOP20210164A1 (ar) 2019-01-11 2023-01-30 Omeros Corp طرق وتركيبات علاج السرطان
CN112625050B (zh) 2019-07-30 2021-10-01 杭州阿诺生物医药科技有限公司 一种a2a和/或a2b受体抑制剂的制备方法
CN112608316B (zh) 2019-07-30 2022-10-21 厦门宝太生物科技股份有限公司 一种吡唑并三嗪类腺苷受体拮抗剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US176399A (en) * 1876-04-18 Improvement in boxes for packing crackers
US23763A (en) * 1859-04-26 Method of adjusting the knives of rotary cutter-heads for planing wood
US42891A (en) * 1864-05-24 Improvement in water-engines
US275038A (en) * 1883-04-03 Ors to themselves
US22106A (en) * 1858-11-23 Truss-bridge
GB9309573D0 (en) * 1993-05-10 1993-06-23 Merck Sharp & Dohme Therapeutic agents
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
NZ521633A (en) * 2000-04-26 2005-01-28 Eisai Co Ltd Use of an adenosine A2 or A2b recpetor antagonist for promoting bowel movement
US6641549B2 (en) * 2001-02-05 2003-11-04 Bsn Medical, Inc. Custom-moldable support for patellar tendinitis
TWI330183B (enExample) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
US20050043315A1 (en) * 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115477653A (zh) * 2022-10-11 2022-12-16 安徽省庆云医药股份有限公司 一种曲拉西利关键中间体及曲拉西利的制备方法
CN115477653B (zh) * 2022-10-11 2024-04-09 安徽省庆云医药股份有限公司 一种曲拉西利关键中间体及曲拉西利的制备方法

Also Published As

Publication number Publication date
ES2229928A1 (es) 2005-04-16
EP1668000A1 (en) 2006-06-14
IL174771A0 (en) 2006-08-20
NO20061952L (no) 2006-06-26
TW200526645A (en) 2005-08-16
US20070265273A1 (en) 2007-11-15
WO2005040155A1 (en) 2005-05-06
ZA200602139B (en) 2007-06-27
CO5690593A2 (es) 2006-10-31
AU2004283800B2 (en) 2009-05-07
SG149077A1 (en) 2009-01-29
NZ546266A (en) 2008-10-31
MXPA06003525A (es) 2006-06-08
ECSP066426A (es) 2006-10-17
JP2007507443A (ja) 2007-03-29
AU2004283800A1 (en) 2005-05-06
ES2229928B1 (es) 2006-07-01
AU2004283800B8 (en) 2009-06-18
PE20050473A1 (es) 2005-08-24
AR046170A1 (es) 2005-11-30
BRPI0415324A (pt) 2006-12-05
WO2005040155A8 (en) 2006-04-20
RU2006114746A (ru) 2007-11-20
UA82563C2 (uk) 2008-04-25
CA2540765A1 (en) 2005-05-06
UY28529A1 (es) 2005-04-29
KR20060097010A (ko) 2006-09-13

Similar Documents

Publication Publication Date Title
CN1886402A (zh) 嘧啶－2－胺衍生物及其作为a2b腺苷受体拮抗剂的用途
CN1168719C (zh) 6-苯基吡啶-2-基胺衍生物以及药物组合物和用途
CN1098263C (zh) 吡啶－2－基－甲胺衍生物、其制备方法及其作为药物的用途
CN1275964C (zh) 作为细胞增殖抑制剂的7－氧代吡啶并嘧啶
CN1400973A (zh) 新的联芳基甲酰胺
CN1950371A (zh) 用作组胺h3受体配体的四氢萘啶衍生物
CN1960988A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN1703414A (zh) 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶
CN1642915A (zh) 用作组蛋白脱乙酰基酶抑制剂的苯甲酰胺衍生物
CN1701073A (zh) 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5－a]嘧啶
CN1582285A (zh) 用作糖原合酶激酶3β抑制剂(GSK3抑制剂)的杂芳胺化合物
CN1662236A (zh) 组蛋白脱乙酰基转移酶抑制剂
CN1278819A (zh) 作为促肾上腺皮质素释放激素拮抗剂、可用于治疗cns障碍和紧张相关性疾病的杂环基取代的环稠合吡啶和嘧啶
CN101044137A (zh) 作为plk抑制剂的2,4－二（氨基苯基）嘧啶
CN1422268A (zh) 5－烷基吡啶并[2,3－d]嘧啶酪氨酸激酶抑制剂
CN1656082A (zh) 蛋白激酶抑制剂
CN1713910A (zh) 作为p38激酶抑制剂的氮杂吲哚衍生物
CN1906190A (zh) 选择性激酶抑制剂
CN1099755A (zh) 环状衍生物、含该衍生物的药物组合物及制备方法
CN1694886A (zh) 作为周期素依赖性激酶抑制剂的咪唑并吡嗪
CN1503672A (zh) 6-取代的吡啶并嘧啶类化合物
CN1177844C (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
CN1768058A (zh) 作为黑皮质素受体激动剂的咪唑并吡啶衍生物
CN1596258A (zh) 腺A2α受体拮抗剂
CN1845915A (zh) 作为亲代谢谷氨酸受体－5的调节剂的联吡啶胺和醚类化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20061227

C20 Patent right or utility model deemed to be abandoned or is abandoned